Blog

CYTX Expands Celution EU Indications; To Support Hospital Sales

July 27, 2010

Cytori (NASDAQ: CYTX) expanded its Celution® System CE Mark by receiving additional indications-for-use, which build upon the existing device approval. The current Celution System indications-for-use allow for the digestion of adipose tissue to extract, wash and concentrate a patient’s own stem cells and other associated cells for re-injection back into the same patient. These new indications add specific medical applications for the re-injection of cells, which include:
 
·   Breast reconstruction;
·   Repair of soft tissue defects, and
·   The facilitation of healing certain types of wounds, such as those resulting from Crohn’s disease
 
The importance of this development is that it improves the ability of our sales force and distributors to offer the Celution® System to hospitals. Until now, our sales activities have been focused mostly on private-pay plastic and cosmetic surgery clinics. Additionally, this supports our effort to gain reimbursement for stem and regenerative cell-enriched breast reconstruction and other reconstructive surgery procedures.
 
Clinical data from our RESTORE 2 breast reconstruction trial in Europe and other wound repair clinical studies were used to support the expanded CE Mark. The CE Mark, in addition to the 27 countries of the EU, is followed by eight additional countries around the world and facilitates other registrations around the world. For more information, please see the attached release.

Tags: No tags
Categories: No categories
 
About This Blog
Visit our shareholder blog to get periodic updates on our company and products as well as occasional commentary on industry developments impacting our business. Members of management as well as other employees will also provide candid insight from time time. Enjoy, Tom

Blog entiries include forward-looking statements regarding events, trends and business prospects, which may affect our future operating results and financial position. Such statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks and uncertainties are described under the "Risk Factors" in Cytori's Securities and Exchange Filings, including its annual report on Form 10-K. Cytori assumes no responsibility to update or revise any forward-looking statements contained in these notes to reflect events, trends or circumstances after the date of these blog entries.

Links to external websites and news and information sources may at times be provided. Any information, views or opinions expressed in these links do not necessarily represent the views of Cytori, nor can Cytori ensure the accuracy of any information contained in external links, in particular is it might relate to Cytori.
Recent Posts
RSS Feed


Close window | Back to top


Copyright 2010 Cytori Therapeutics